Abstract
Background Salmonella enterica serovar Typhi (S. Typhi), the causative agent of Typhoid fever, is transmitted faecal-orally. Some typhoid sufferers shed S. Typhi beyond convalescence, but culturing stool following every case is impractical. Here we hypothesised that serology might direct testing and identify shedding after a typhoid outbreak.
Methodology/Principle Findings In 2016 there was a typhoid outbreak in a Nursing School in Malosa, Malawi. We collected serum three and six-months post-outbreak. We measured IgG antibody titres against Vi capsular polysaccharide (anti-Vi IgG) and IgM / IgG antibodies against H:d flagellin (anti-H:d). We screened faecal samples from participants with high and low anti-Vi IgG (measured at visit one) by culture and PCR. Participants reported whether they had persistent fever for ≥ three days (in keeping with World Health Organization definitions for typhoid) during the outbreak. We tested for environmental S. Typhi.
368 people provided serum at 3-months, of whom 320 provided serum at 6-months; 49 participants provided a faecal sample (25 from the highest and 24 from the lowest deciles for anti-Vi IgG titre). We did not grow S. Typhi from faeces, but one sample produced a positive PCR amplification for S. Typhi. Median anti-Vi IgG titre fell amongst participants with persistent fever (8.08 to 3.7 EU/ml, <0.000001, Wilcoxon signed rank). Median anti-H:d IgG titres fell in those with and without persistent fever (87.8 to 77.4 EU/, p = <0.000001 and 82.4 to 79.2 EU/ml, p = 0.0002, Wilcoxon signed rank, respectively). Anti-H:d IgM titres did not change significantly. Non-Typhoidal Salmonellae were identified in water sampled at source and a kitchen tap.
Conclusions / Significance We did not identify culture-confirmed shedding through sero-surveillance. Serologic trends signify a fall from an outbreak-associated peak. Despite effective vaccines, identifying ways to detect and treat shedding remain vital to break transmission and eliminate typhoid.
Author Summary Typhoid fever spreads by the faecal-oral route. Some people continue to shed the bacterium that causes typhoid (Salmonella enterica serovar Typhi, or S. Typhi) after recovering from the illness. To stop onward spread it is important that these people are identified and treated.
Shedders are detected when S. Typhi grows from faeces, but it is not practical to obtain stool samples from large populations. Following a typhoid outbreak we tested whether a subset of participants with high antibodies to S. Typhi proteins contained more shedders than a subset with low antibody responses. We tested whether antibody levels changed in the months after the outbreak, to inform whether they are useful markers of exposure in a population.
We did not grow S. Typhi. This may be because our population had few risk factors for S. Typhi carriage, or because exposure to other endemic bacteria influence antibody levels. We saw a decline in antibody levels over time, most marked in those who reported fever during the outbreak. We think that this reflects a response to recent infection. It is important to continue to evaluate ways of finding carriers so that, combined with vaccines and improved sanitation, we can one day eliminate typhoid.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by a grant from the Bill and Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Malawi College of Medicine Research Ethics Committee (COMREC), P.10/16/2043.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors